149 related articles for article (PubMed ID: 12188889)
1. Challenges of cancer drug design: a drug metabolism perspective.
Sanchez RI; Mesia-Vela S; Kauffman FC
Curr Cancer Drug Targets; 2001 May; 1(1):1-32. PubMed ID: 12188889
[TBL] [Abstract][Full Text] [Related]
2. Targeting drug-metabolizing enzymes for effective chemoprevention and chemotherapy.
Swanson HI; Njar VC; Yu Z; Castro DJ; Gonzalez FJ; Williams DE; Huang Y; Kong AN; Doloff JC; Ma J; Waxman DJ; Scott EE
Drug Metab Dispos; 2010 Apr; 38(4):539-44. PubMed ID: 20233842
[TBL] [Abstract][Full Text] [Related]
3. Molecular biological design of novel antineoplastic therapies.
Vulfovich M; Saba N
Expert Opin Investig Drugs; 2004 Jun; 13(6):577-607. PubMed ID: 15174947
[TBL] [Abstract][Full Text] [Related]
4. Advances in the use of angiogenesis inhibitors in cancer.
Pinedo HM
Cancer J; 2001; 7 Suppl 3():S107-8. PubMed ID: 11779080
[No Abstract] [Full Text] [Related]
5. Pharmacogenetics and cancer chemotherapy.
Iyer L; Ratain MJ
Eur J Cancer; 1998 Sep; 34(10):1493-9. PubMed ID: 9893619
[TBL] [Abstract][Full Text] [Related]
6. Angiogenesis inhibitors.
Tennant TR; Rinker-Schaeffer CW; Stadler WM
Curr Oncol Rep; 2000 Jan; 2(1):11-6. PubMed ID: 11122819
[TBL] [Abstract][Full Text] [Related]
7. Drug-metabolizing enzymes: mechanisms and functions.
Sheweita SA
Curr Drug Metab; 2000 Sep; 1(2):107-32. PubMed ID: 11465078
[TBL] [Abstract][Full Text] [Related]
8. Understanding the role of xenobiotic-metabolism in chemical carcinogenesis using gene knockout mice.
Gonzalez FJ; Kimura S
Mutat Res; 2001 Jun; 477(1-2):79-87. PubMed ID: 11376689
[TBL] [Abstract][Full Text] [Related]
9. Effect of chlorpromazine hydrochloride on carcinogen-metabolizing enzymes: liver microsomal dimethylnitrosamine demethylase, 4-dimethylaminoazobenzene reductase, and aryl hydrocarbon hydroxylase.
Mostafa MH; Weisburger EK
J Natl Cancer Inst; 1980 Apr; 64(4):925-9. PubMed ID: 6767870
[TBL] [Abstract][Full Text] [Related]
10. Cytochrome P450 1B1: a novel anticancer therapeutic target.
McFadyen MC; Murray GI
Future Oncol; 2005 Apr; 1(2):259-63. PubMed ID: 16555997
[TBL] [Abstract][Full Text] [Related]
11. Pharmacogenetics in cancer chemotherapy: balancing toxicity and response.
Donnelly JG
Ther Drug Monit; 2004 Apr; 26(2):231-5. PubMed ID: 15228171
[TBL] [Abstract][Full Text] [Related]
12. Epigenetic approach for angiostatic therapy: promising combinations for cancer treatment.
Berndsen RH; Abdul UK; Weiss A; Zoetemelk M; Te Winkel MT; Dyson PJ; Griffioen AW; Nowak-Sliwinska P
Angiogenesis; 2017 May; 20(2):245-267. PubMed ID: 28378227
[TBL] [Abstract][Full Text] [Related]
13. Different levels of Schistosoma mansoni infection induce changes in drug-metabolizing enzymes.
Sheweita SA; Mangoura SA; el-Shemi AG
J Helminthol; 1998 Mar; 72(1):71-7. PubMed ID: 9639905
[TBL] [Abstract][Full Text] [Related]
14. 'Accidental' anti-angiogenic drugs. anti-oncogene directed signal transduction inhibitors and conventional chemotherapeutic agents as examples.
Kerbel RS; Viloria-Petit A; Klement G; Rak J
Eur J Cancer; 2000 Jun; 36(10):1248-57. PubMed ID: 10882863
[TBL] [Abstract][Full Text] [Related]
15. Farnesyltransferase inhibitors: mechanism and applications.
Prendergast GC; Rane N
Expert Opin Investig Drugs; 2001 Dec; 10(12):2105-16. PubMed ID: 11772308
[TBL] [Abstract][Full Text] [Related]
16. The procarcinogen hypothesis for bladder cancer: activities of individual drug metabolizing enzymes as risk factors.
Branch RA; Chern HD; Adedoyin A; Romkes-Sparks M; Lesnick TG; Persad R; Wilkinson GR; Fleming CM; Dickinson AJ; Sibley G
Pharmacogenetics; 1995; 5 Spec No():S97-102. PubMed ID: 7581498
[TBL] [Abstract][Full Text] [Related]
17. Induction of drug-metabolizing enzymes: mechanisms and consequences.
Okey AB; Roberts EA; Harper PA; Denison MS
Clin Biochem; 1986 Apr; 19(2):132-41. PubMed ID: 3518989
[TBL] [Abstract][Full Text] [Related]
18. Cytochrome P450, drug metabolizing enzymes and arachidonic acid metabolism in bovine ocular tissues.
Schwartzman ML; Masferrer J; Dunn MW; McGiff JC; Abraham NG
Curr Eye Res; 1987 Apr; 6(4):623-30. PubMed ID: 3107908
[TBL] [Abstract][Full Text] [Related]
19. Molecular mechanisms and therapeutic development of angiogenesis inhibitors.
Cao Y
Adv Cancer Res; 2008; 100():113-31. PubMed ID: 18620094
[TBL] [Abstract][Full Text] [Related]
20. Human cytochrome p450 enzymes of importance for the bioactivation of methyleugenol to the proximate carcinogen 1'-hydroxymethyleugenol.
Jeurissen SM; Bogaards JJ; Boersma MG; ter Horst JP; Awad HM; Fiamegos YC; van Beek TA; Alink GM; Sudhölter EJ; Cnubben NH; Rietjens IM
Chem Res Toxicol; 2006 Jan; 19(1):111-6. PubMed ID: 16411663
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
